Galapagos
GLPGPhase 3We are scientists, entrepreneurs, and pioneers united around a single purpose: to transform patient outcomes through life-changing science and innovation for more years of life and quality of life for people around the world.
Market Cap
$2.1B
Focus
AntibodiesBiologicsSmall Molecules
GLPG · Stock Price
USD 32.0130.16 (-48.51%)
Historical price data
About
We are scientists, entrepreneurs, and pioneers united around a single purpose: to transform patient outcomes through life-changing science and innovation for more years of life and quality of life for people around the world.
Pipeline Snapshot
108108 drugs in pipeline, 3 in Phase 3
| Drug | Indication | Stage |
|---|---|---|
| Filgotinib + Anti-Tumor Necrosis Factor Alpha Drug (Product) | Rheumatoid Arthritis | Approved |
| Filgotinib + Adalimumab | Rheumatoid Arthritis | Approved |
| Filgotinib + Placebo | Ulcerative Colitis | Phase 3 |
| GLPG1690 + Placebo | Idiopathic Pulmonary Fibrosis | Phase 3 |
| GLPG1690 + Placebo | Idiopathic Pulmonary Fibrosis | Phase 3 |
Funding History
2Total raised: $100M
PIPE$100MGilead SciencesJul 15, 2019
IPOUndisclosedUndisclosedMay 5, 2005
Publications
19
Patents
20
Pipeline
108
Company Info
TypePublic
LocationBelgium
StagePhase 3
Contact
SIMILAR COMPANIES
Miracor Medical
Pre-clinical · Zaventem
AML Clinical Services
Pre-clinical · Leuven
Anacura
Pre-clinical · Ghent
Aseptic Technologies
Pre-clinical · Gembloux
Aspect Analytics
Pre-clinical · Leuven
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile